Resources

  • Article

    Regeneron, Janssen Drugs Fit Profile Targeted in Spending Bill
    11.10.2021

    Plan would negotiate prices of expensive older pharmaceuticals Moderate Democrats sought compromise to preserve innovation

  • Article

    Drug pricing bill’s unintended consequences will distort drug development
    11.09.2021

    The ultimate victims of all the unintended consequences of the current proposal will be all of us as future patients.

  • Statement

    Leading Venture Capital Group Concerned with Prescription Drug Deal
    11.04.2021

    "As investors in biotechnology and pharmaceuticals, we're highly concerned about the potential consequences of the new drug-pricing legislation before Congress in the Build Back Better Act."

  • Article

    Leading Venture Capital Group Concerned with Prescription Drug Deal
    11.04.2021

    Investors in biotechnology and pharmaceuticals aere concerned about the potential consequences of the new drug-pricing legislation before Congress in the Build Back Better Act.

  • Policy Lab

    Drug Price Controls in the U.S.: A Roundtable Discussion with Experts
    10.20.2021

    This report attempts to better understand the potential effect of price-setting policies such as H.R.3 on pharmaceutical innovation.

  • Article

    Cost of Care: Rare diseases expose need to revamp US drug pricing policy
    10.20.2021

    Developing more effective treatments for patients with no other options while also keeping costs down will require a balancing act with no clear solution

  • Article

    Democrats’ Drug Price Controls Threaten Biotech Research, Patients
    09.21.2021

    Biotech investors sounded alarms at the National Press Club last week about what they would mean. They said the price-control scheme would dry up investor interest in the biotech sector.

  • Article

    VC Daily: Venture Capitalists Push Back Against Drug-Pricing Bill
    09.16.2021

    If price controls are enacted on drugs, investment will no longer flow to innovative new biotech treatments

  • Article

    Venture firms warn R&D funding for new drugs will ‘drop off a cliff’ if Dem bill approved
    09.16.2021

    Democrats move forward with giving Medicare the power to negotiate drug prices for certain drugs and extend those prices to commercial plans.

  • Article

    Cost of Care: Biotech VCs fret over ‘thumb on the scale’ Medicare reform plans
    09.15.2021

    For venture capitalists investing in companies at the earliest stages of scientific discovery and drug development, the ramifications of pricing control could change the landscape in ways that vastly undermine future funding decisions

  • Statement

    Statement in response to the release of the Reduced Costs and Continued Cures Act
    09.15.2021

  • Policy Lab

    SIGNAL WATCHING: How Life Science Venture Capital Perceives Medicare Part D Reforms
    09.10.2021

    This report examines proposed changes to Part D from the lens of the early-stage life science research ecosystem.